From RTTNews:

Eli Lilly and Co. reported a 13 percent profit increase for the fourth quarter, with both adjusted earnings per share and revenues surpassing analyst expectations. The company cited strong Mounjaro sales and higher prices as contributing factors. Pre-market trading saw LLY shares up 4.79 percent to $740.00. Net income for the quarter was $2.19 billion or $2.42 per share, and adjusted earnings were $2.49 per share. Worldwide revenue grew 28 percent to $9.35 billion, driven by various products including Mounjaro, Verzenio, and Jardiance. The company projected strong revenue guidance for the full-year 2024, with earnings in a range of $11.80 to $12.30 per share and adjusted earnings in a range of $12.20 to $12.70 per share on revenues between $40.4 billion and $41.6 billion.



Read more: Eli Lilly Q4 Results Top Estimates